WO2018229785A1 - Pharmaceutical compositions of ticagrelor - Google Patents

Pharmaceutical compositions of ticagrelor Download PDF

Info

Publication number
WO2018229785A1
WO2018229785A1 PCT/IN2017/050324 IN2017050324W WO2018229785A1 WO 2018229785 A1 WO2018229785 A1 WO 2018229785A1 IN 2017050324 W IN2017050324 W IN 2017050324W WO 2018229785 A1 WO2018229785 A1 WO 2018229785A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
ticagrelor
composition according
pharmaceutically acceptable
polymer
Prior art date
Application number
PCT/IN2017/050324
Other languages
French (fr)
Inventor
Ashok THADISETTY
Krishna Murthy Bhavanasi
Lakshmi Venkata Pavan Kumar KOTA
Pavan Bhat
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Publication of WO2018229785A1 publication Critical patent/WO2018229785A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the invention relates to oral pharmaceutical compositions comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1 : 1 in the form of solid dispersion and process for the preparation of such compositions.
  • Ticagrelor a cyclopentyltriazolopyrimidine, inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP-receptor.
  • Chemically it is (lS,2S,3R,5S)-3- [7- ⁇ [(lR,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino ⁇ -5(propylthio)-3H-[l,2,3]- triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol.
  • the structural formula is:
  • U.S. Patent No. 8,425,934 discloses a pharmaceutical composition
  • a pharmaceutical composition comprising ticagrelor, a filler consisting essentially of a mixture of mannitol and di basic calcium phosphate dihydrate, a binder consisting essentially of hydroxypropyl cellulose, a disintegrant consisting essentially of sodium starch glycolate, and one or more lubricants.
  • the compositions are prepared by using a wet granulation process or a high shear wet granulation process.
  • U.S. Publication No. 2008/0045548 discloses a pharmaceutical composition of ticagrelor suitable for oral administration that releases substantially all of the drug substance.
  • PCT Publication No. WO 2011/076749 discloses solid dosage forms comprising ticagrelor, characterized in that at least 90% by volume of ticagrelor particles have a particle size in the range of 1 ⁇ to 150 ⁇ .
  • PCT Publication No. WO 2015/110952 discloses process of preparing solid oral pharmaceutical composition of ticag
  • Ticagrelor is classified as BCS class IV compound, exhibiting low solubility and low permeability. This property leads to an undesirable dissolution profile and hence poor bioavailability. It also leads to high intra-subject and inter-subject variability following oral administration.
  • amorphous form of drug substance has higher solubility as compared to the crystalline form and more hygroscopic and less stable than the crystalline form. This makes formulating amorphous form is challenging.
  • the present application discloses that the dissolution of ticagrelor can be improved by using the drug in its amorphous form.
  • a pharmaceutical composition comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1: 1 in the form of solid dispersion.
  • Embodiments of the present invention may include one or more of the following features for example the pharmaceutical composition may further include one or more pharmaceutical acceptable excipients.
  • the pharmaceutical acceptable excipients may include diluents, binders, disintegrants, surfactants, lubricants, glidants and the like.
  • the invention provides provided a pharmaceutical composition
  • a pharmaceutical composition comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1: 1 in the form of solid dispersion.
  • the pharmaceutical composition comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1 : 1 in the form of solid dispersion and one or more pharmaceutically acceptable excipients include diluents, binders, disintegrants, surfactants, lubricants, glidants and the like.
  • the ratio of Ticagrelor to polymer is 1:0.2 to 1:0.8. Preferably, 1 :0.5.
  • the Ticagrelor is molecularly dispersed in polymer matrix.
  • the pharmaceutical composition comprises Ticagrelor in crystalline or amorphous form.
  • the pharmaceutical composition comprises crystalline form N of Ticagrelor.
  • the pharmaceutical composition comprises amorphous Ticagrelor.
  • the pharmaceutically acceptable polymer is water soluble polymer.
  • Water soluble polymers include, but not limited to polyvinylpyrrolidone, copovidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol and polyethylene oxide. Preferably, povidone.
  • the solid dispersion is prepared by methods known to the art for the manufacture of solid dispersions, such as fusion/melt technology, hot melt extrusion, hot melt coating, prilling, congealing, solvent evaporation (e.g. freeze drying, spray drying, vacuum drying, layering of powders, granules or pellets and fluid bed granulation), coprecipitation, supercritical fluid technology and electrostatic spinning method.
  • solvent evaporation or hot melt extrusion e.g. freeze drying, spray drying, vacuum drying, layering of powders, granules or pellets and fluid bed granulation
  • coprecipitation e.g. freeze drying, spray drying, vacuum drying, layering of powders, granules or pellets and fluid bed granulation
  • Solvent suitable for manufacture of solid dispersion by solvent evaporation processes include, but not limited to methanol, ethanol, n-propanol, isopropanol, butanol, acetone, methyl ethyl ketone and methyl isobutyl ketone, ethyl acetate, propyl acetate, acetonitrile, methylene chloride, chloroform, hexane, toluene, tetrahydrofuran, cyclic ethers, 1, 1,1-trichloroethane, dimethyl acetamide, dimethyl sulfoxide or mixtures thereof.
  • the pharmaceutical composition is in the form of powder, granules, pellets, tablets, capsules, dragees, chewable tablets, effervescent tablets, dispersible tablets, troches, lozenges, melts, solutions, suspensions, or emulsions, and may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions.
  • the pharmaceutical composition is in the form of tablet. In another embodiment, the tablet is film coated.
  • the film coat comprises film-forming polymers and one or more pharmaceutically acceptable excipients.
  • the process for the preparation of the pharmaceutical composition comprises the steps of:
  • the process for the preparation of the pharmaceutical composition comprises the steps of: i. preparing solid dispersion containing ticagrelor and pharmaceutically acceptable water soluble polymer in a ratio of 1 :0.5 in a suitable solvent by solvent evaporation process.
  • step 1 ii. blending solid dispersion of step 1 and one or more pharmaceutically acceptable excipients.
  • the solid dispersion comprising ticagrelor in substantially amorphous form.
  • the pharmaceutically acceptable excipients diluents, binders, disintegrants, surfactants, lubricants, glidants and the like.
  • Diluent includes, but are not limited to, powdered cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, starch, dibasic calcium phosphate, tribasic calcium phosphate, calcium carbonate, dextrates, dextrin, dextrose, kaolin, magnesium carbonate, magnesium oxide, sugars such as sucrose; sugar alcohols such as mannitol, sorbitol, erythritol; and mixtures thereof.
  • Binder includes, but are not limited to, carrageenan, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carbomers, carboxymethylcellulose sodium, dextrin, ethyl cellulose, methylcellulose, shellac, zein, gelatin, polymethacrylates, polyvinyl pyrrolidone, pregelatinized starch, sodium alginate, gums, synthetic resins and the like.
  • Disintegrant includes, but are not limited to, croscarmellose sodium, sodium starch glycolate, pregelatinized starch, sodium carboxymethyl cellulose, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, sodium alginate and mixtures thereof.
  • Surfactant includes, but are not limited to, sodium lauryl sulfate, sodium dodecyl sulfate, ammonium lauryl sulfate, benzalkonium chloride, alkyl poly (ethylene oxide), copolymers of poly (ethylene oxide) and poly (propylene oxide) commercially called as poloxamers or poloxamines, polyvinyl alcohol, fatty alcohols, polyoxyethylene alkyl ether, polyoxyethylene alkylaryl ether, polyethylene glycol fatty acid ester, alkylene glycol fatty acid mono ester, sucrose fatty acid ester, and sorbitan fatty acid mono ester, sorbitol monolaurate or mixtures thereof.
  • Lubricant includes, but are not limited to, metallic stearates such as magnesium stearate, calcium stearate, zinc stearate; stearic acid, hydrogenated vegetable oil, hydrogenated castor oil, glyceryl palmitostearate, glyceryl behenate, polyethylene glycols, corn starch, sodium stearyl fumarate, sodium benzoate, mineral oil, talc, and mixtures thereof.
  • metallic stearates such as magnesium stearate, calcium stearate, zinc stearate
  • stearic acid hydrogenated vegetable oil, hydrogenated castor oil, glyceryl palmitostearate, glyceryl behenate, polyethylene glycols, corn starch, sodium stearyl fumarate, sodium benzoate, mineral oil, talc, and mixtures thereof.
  • Glidant includes, but are not limited to, colloidal silicon dioxide, calcium silicate, magnesium silicate, silicon hydrogel, cornstarch, talc, or mixtures thereof.
  • Film-forming agents include, but are not limited to, cellulose derivatives such as methylcellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl ethylcellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, and ethyl cellulose; waxes; fat substances; or mixtures thereof.
  • commercially available coating compositions comprising film forming polymers marketed under various trade names, such as Opadry®, may be used for coating.
  • Solvents used for preparing the coating solution include, but not limited to methyl alcohol, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, acetone, acetonitrile, chloroform, methylene chloride, water, or mixtures thereof.
  • the pharmaceutical composition of the present invention is useful for the treatment of cardiovascular diseases such as thrombotic cardiovascular events selected from unstable angina, myocardial infarction, stroke, transient ischaemic attacks, or peripheral vascular disease in patients with acute coronary syndrome (ACS).
  • cardiovascular diseases such as thrombotic cardiovascular events selected from unstable angina, myocardial infarction, stroke, transient ischaemic attacks, or peripheral vascular disease in patients with acute coronary syndrome (ACS).
  • Ticagrelor and copovidone are dissolved in sufficient quantity of ethanol.
  • solution of step-i is spray dried using spray dryer followed by tray drying to obtain amorphous ticagrelor.
  • step-iii solid dispersion of step-ii is blended with mannitol, calcium hydrogen phosphate anhydrous, microcrystalline cellulose PH102 and croscarmellose sodium for 10 min.
  • iv. blend is lubricated with magnesium stearate for 2 min.
  • v. lubricated blend is subjected to roller compaction followed by milling to obtain the granules.
  • step-v granules of step-v are blended microcrystalline cellulose PHI 02 and croscarmellose sodium.
  • step-vi blend of step-vi is lubricated with magnesium stearate.
  • Ticagrelor and copovidone are extruded through hot melt extruder followed by milling to obtain granules.
  • Granules containing amorphous ticagrelor is blended with mannitol, calcium hydrogen phosphate anhydrous, microcrystalline cellulose phi 02 and croscarmellose sodium for 10 min. iii.
  • the blend is lubricated with magnesium stearate for 2 min.

Abstract

The invention relates to oral pharmaceutical compositions comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1:1 in the form of solid dispersion and process for the preparation of such compositions.

Description

PHARMACEUTICAL COMPOSITIONS OF TICAGRELOR
FIELD OF THE INVENTION
The invention relates to oral pharmaceutical compositions comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1 : 1 in the form of solid dispersion and process for the preparation of such compositions.
BACKGROUND OF THE INVENTION
Ticagrelor, a cyclopentyltriazolopyrimidine, inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP-receptor. Chemically it is (lS,2S,3R,5S)-3- [7-{ [(lR,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5(propylthio)-3H-[l,2,3]- triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol. The structural formula is:
Figure imgf000002_0001
TICAGRELOR
PCT Publication No. WO 00/34283 discloses ticagrelor as a compound and U.S. Patent No. 7,265,124 discloses various polymorphs of ticagrelor.
U.S. Patent No. 8,425,934 discloses a pharmaceutical composition comprising ticagrelor, a filler consisting essentially of a mixture of mannitol and di basic calcium phosphate dihydrate, a binder consisting essentially of hydroxypropyl cellulose, a disintegrant consisting essentially of sodium starch glycolate, and one or more lubricants. The compositions are prepared by using a wet granulation process or a high shear wet granulation process.
U.S. Publication No. 2008/0045548 discloses a pharmaceutical composition of ticagrelor suitable for oral administration that releases substantially all of the drug substance.
PCT Publication No. WO 2011/076749 discloses solid dosage forms comprising ticagrelor, characterized in that at least 90% by volume of ticagrelor particles have a particle size in the range of 1 μιτι to 150 μιτι.
PCT Publication No. WO 2015/110952 discloses process of preparing solid oral pharmaceutical composition of ticag
Ticagrelor is classified as BCS class IV compound, exhibiting low solubility and low permeability. This property leads to an undesirable dissolution profile and hence poor bioavailability. It also leads to high intra-subject and inter-subject variability following oral administration.
In general, amorphous form of drug substance has higher solubility as compared to the crystalline form and more hygroscopic and less stable than the crystalline form. This makes formulating amorphous form is challenging. The present application discloses that the dissolution of ticagrelor can be improved by using the drug in its amorphous form.
Thus, there exists a need to prepare alternate ticagrelor compositions that are stable and provide the desired dissolution and bioavailability. SUMMARY OF THE INVENTION
In one general aspect, there is provided a pharmaceutical composition comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1: 1 in the form of solid dispersion.
Embodiments of the present invention may include one or more of the following features for example the pharmaceutical composition may further include one or more pharmaceutical acceptable excipients. The pharmaceutical acceptable excipients may include diluents, binders, disintegrants, surfactants, lubricants, glidants and the like.
The details of one or more embodiments of the present invention are set forth in the description below. Other features, objects and advantages of the invention will be apparent from the description.
DETAILED DESCRIPTION OF THE INVENTION
The invention provides provided a pharmaceutical composition comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1: 1 in the form of solid dispersion.
In an embodiment, the pharmaceutical composition comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1 : 1 in the form of solid dispersion and one or more pharmaceutically acceptable excipients include diluents, binders, disintegrants, surfactants, lubricants, glidants and the like.
In another embodiment, the ratio of Ticagrelor to polymer is 1:0.2 to 1:0.8. Preferably, 1 :0.5.
In another embodiment, the Ticagrelor is molecularly dispersed in polymer matrix. In another embodiment, the pharmaceutical composition comprises Ticagrelor in crystalline or amorphous form.
In another embodiment, the pharmaceutical composition comprises crystalline form N of Ticagrelor.
In another embodiment, the pharmaceutical composition comprises amorphous Ticagrelor.
In another embodiment, the pharmaceutically acceptable polymer is water soluble polymer.
Water soluble polymers include, but not limited to polyvinylpyrrolidone, copovidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol and polyethylene oxide. Preferably, povidone.
The solid dispersion is prepared by methods known to the art for the manufacture of solid dispersions, such as fusion/melt technology, hot melt extrusion, hot melt coating, prilling, congealing, solvent evaporation (e.g. freeze drying, spray drying, vacuum drying, layering of powders, granules or pellets and fluid bed granulation), coprecipitation, supercritical fluid technology and electrostatic spinning method. Preferably, solvent evaporation or hot melt extrusion.
Solvent suitable for manufacture of solid dispersion by solvent evaporation processes include, but not limited to methanol, ethanol, n-propanol, isopropanol, butanol, acetone, methyl ethyl ketone and methyl isobutyl ketone, ethyl acetate, propyl acetate, acetonitrile, methylene chloride, chloroform, hexane, toluene, tetrahydrofuran, cyclic ethers, 1, 1,1-trichloroethane, dimethyl acetamide, dimethyl sulfoxide or mixtures thereof. Preferably, methanol, ethanol, isopropanol or acetone. More preferably, ethanol or acetone.
In another embodiment, the pharmaceutical composition is in the form of powder, granules, pellets, tablets, capsules, dragees, chewable tablets, effervescent tablets, dispersible tablets, troches, lozenges, melts, solutions, suspensions, or emulsions, and may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions.
In another embodiment, the pharmaceutical composition is in the form of tablet. In another embodiment, the tablet is film coated.
The film coat comprises film-forming polymers and one or more pharmaceutically acceptable excipients.
In another embodiment, the process for the preparation of the pharmaceutical composition comprises the steps of:
i. preparing solid dispersion containing ticagrelor and pharmaceutically acceptable water soluble polymer in a ratio of 1:0.5 by hot melt extrusion. ii. milling the extrudes to obtain granules.
iii. blending granules with one or more pharmaceutically acceptable excipients. iv. lubricating the granules
v. compressing the lubricated granules into tablets.
In another embodiment, the process for the preparation of the pharmaceutical composition comprises the steps of: i. preparing solid dispersion containing ticagrelor and pharmaceutically acceptable water soluble polymer in a ratio of 1 :0.5 in a suitable solvent by solvent evaporation process.
ii. blending solid dispersion of step 1 and one or more pharmaceutically acceptable excipients.
iii. lubricating the blend
iv. compacting the blend to obtain granules
v. lubricating the granules
vi. compressing the lubricated granules into tablets.
In another embodiment, the solid dispersion comprising ticagrelor in substantially amorphous form.
The pharmaceutically acceptable excipients diluents, binders, disintegrants, surfactants, lubricants, glidants and the like.
Diluent includes, but are not limited to, powdered cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, starch, dibasic calcium phosphate, tribasic calcium phosphate, calcium carbonate, dextrates, dextrin, dextrose, kaolin, magnesium carbonate, magnesium oxide, sugars such as sucrose; sugar alcohols such as mannitol, sorbitol, erythritol; and mixtures thereof.
Binder includes, but are not limited to, carrageenan, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carbomers, carboxymethylcellulose sodium, dextrin, ethyl cellulose, methylcellulose, shellac, zein, gelatin, polymethacrylates, polyvinyl pyrrolidone, pregelatinized starch, sodium alginate, gums, synthetic resins and the like. Disintegrant includes, but are not limited to, croscarmellose sodium, sodium starch glycolate, pregelatinized starch, sodium carboxymethyl cellulose, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, sodium alginate and mixtures thereof.
Surfactant includes, but are not limited to, sodium lauryl sulfate, sodium dodecyl sulfate, ammonium lauryl sulfate, benzalkonium chloride, alkyl poly (ethylene oxide), copolymers of poly (ethylene oxide) and poly (propylene oxide) commercially called as poloxamers or poloxamines, polyvinyl alcohol, fatty alcohols, polyoxyethylene alkyl ether, polyoxyethylene alkylaryl ether, polyethylene glycol fatty acid ester, alkylene glycol fatty acid mono ester, sucrose fatty acid ester, and sorbitan fatty acid mono ester, sorbitol monolaurate or mixtures thereof.
Lubricant includes, but are not limited to, metallic stearates such as magnesium stearate, calcium stearate, zinc stearate; stearic acid, hydrogenated vegetable oil, hydrogenated castor oil, glyceryl palmitostearate, glyceryl behenate, polyethylene glycols, corn starch, sodium stearyl fumarate, sodium benzoate, mineral oil, talc, and mixtures thereof.
Glidant includes, but are not limited to, colloidal silicon dioxide, calcium silicate, magnesium silicate, silicon hydrogel, cornstarch, talc, or mixtures thereof.
Film-forming agents include, but are not limited to, cellulose derivatives such as methylcellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl ethylcellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, and ethyl cellulose; waxes; fat substances; or mixtures thereof. Alternatively, commercially available coating compositions comprising film forming polymers marketed under various trade names, such as Opadry®, may be used for coating. Solvents used for preparing the coating solution include, but not limited to methyl alcohol, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, acetone, acetonitrile, chloroform, methylene chloride, water, or mixtures thereof.
In another embodiment, the pharmaceutical composition of the present invention is useful for the treatment of cardiovascular diseases such as thrombotic cardiovascular events selected from unstable angina, myocardial infarction, stroke, transient ischaemic attacks, or peripheral vascular disease in patients with acute coronary syndrome (ACS).
The invention is further illustrated by the following examples which are provided to be exemplary of the invention and do not limit the scope of the invention. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Examples
Example -1
Table 1
Figure imgf000009_0001
7 Microcrystalline cellulose PHI 02 84.00
8 Magnesium stearate 2.00
Extra granular
9 Croscarmellose sodium 40.00
10 Microcrystalline cellulose PHI 02 100.00
11 Magnesium stearate 4.00
Coating
12 Opadry 13.8
13 Purified water q.s
Manufacturing process: i. Ticagrelor and copovidone are dissolved in sufficient quantity of ethanol. ii. solution of step-i is spray dried using spray dryer followed by tray drying to obtain amorphous ticagrelor.
iii. solid dispersion of step-ii is blended with mannitol, calcium hydrogen phosphate anhydrous, microcrystalline cellulose PH102 and croscarmellose sodium for 10 min.
iv. blend is lubricated with magnesium stearate for 2 min.
v. lubricated blend is subjected to roller compaction followed by milling to obtain the granules.
vi. granules of step-v are blended microcrystalline cellulose PHI 02 and croscarmellose sodium.
vii. blend of step-vi is lubricated with magnesium stearate.
viii. compressing the lubricated blend into tablets,
ix. Coating the tablets with opadry solution. Film coated tablets of Ticagrelor are packed in Alu-Alu Blisters and HDPE bottles and stored at the accelerated stability testing conditions of 40°C and 75% RH. The impurity content is analyzed by HPLC at intervals and results are show below:
Figure imgf000011_0001
Example -2
Table 2
Figure imgf000011_0002
Manufacturing process:
i. Ticagrelor and copovidone are extruded through hot melt extruder followed by milling to obtain granules.
ii. Granules containing amorphous ticagrelor is blended with mannitol, calcium hydrogen phosphate anhydrous, microcrystalline cellulose phi 02 and croscarmellose sodium for 10 min. iii. The blend is lubricated with magnesium stearate for 2 min.
iv. compressing the lubricated blend into tablets.
v. Coating the tablets with opadry solution.
Dissolution Data
The following table depicts the dissolution profile of examples 1 and 2 in comparison with Brillianta (USP Type II apparatus, 0.2 % w/v Polysorbate 80 in water, 900 ml, 75 rpm).
Table 3
Figure imgf000012_0001

Claims

We Claim:
1. A pharmaceutical composition comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1 : 1 in the form of solid dispersion.
2. The pharmaceutical composition according to claim 1, wherein the ratio of ticagrelor and polymer is 1 :0.2 to 1:0.8.
3. The pharmaceutical composition according to claim 1, wherein the ratio of ticagrelor and polymer is 1 :0.5.
4. The pharmaceutical composition according to claim 1, wherein the ticagrelor is molecularly dispersed in polymeric matrix.
5. The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable polymer is water soluble polymer.
6. The pharmaceutical composition according to claim 5, wherein the pharmaceutically acceptable polymer is polyvinylpyrrolidone, copovidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol or polyethylene oxide
7. The pharmaceutical composition according to claim 1, wherein the ticagrelor is in substantially amorphous form.
8. The pharmaceutical composition according to claim 6, wherein the solid dispersion is prepared by solvent evaporation or hot melt extrusion.
9. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients include diluents, binders, disintegrants, surfactants, lubricants, glidants.
10. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is tablet.
PCT/IN2017/050324 2017-06-15 2017-08-07 Pharmaceutical compositions of ticagrelor WO2018229785A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741020895 2017-06-15
IN201741020895 2017-06-15

Publications (1)

Publication Number Publication Date
WO2018229785A1 true WO2018229785A1 (en) 2018-12-20

Family

ID=64659701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2017/050324 WO2018229785A1 (en) 2017-06-15 2017-08-07 Pharmaceutical compositions of ticagrelor

Country Status (1)

Country Link
WO (1) WO2018229785A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021096444A1 (en) * 2019-11-13 2021-05-20 Santa Farma İlaç Sanayi̇ A.Ş. Pharmaceutical compositions comprising ticagrelor
CN113181140A (en) * 2021-05-07 2021-07-30 苏州康恒研新药物技术有限公司 Ticagrelor skeleton sustained-release pellet and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039513A1 (en) * 2013-09-22 2015-03-26 成都盛迪医药有限公司 Ticagrelor solid dispersion and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039513A1 (en) * 2013-09-22 2015-03-26 成都盛迪医药有限公司 Ticagrelor solid dispersion and preparation method thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021096444A1 (en) * 2019-11-13 2021-05-20 Santa Farma İlaç Sanayi̇ A.Ş. Pharmaceutical compositions comprising ticagrelor
EP4058025A4 (en) * 2019-11-13 2023-08-02 Santa Farma Ilaç Sanayi A.S. Pharmaceutical compositions comprising ticagrelor
CN113181140A (en) * 2021-05-07 2021-07-30 苏州康恒研新药物技术有限公司 Ticagrelor skeleton sustained-release pellet and preparation method thereof

Similar Documents

Publication Publication Date Title
US10874671B2 (en) Pharmaceutical compositions of nilotinib
KR101156916B1 (en) Pharmaceutical compositions comprising imatinib and a release retardant
EP2054040B1 (en) Method for making solid dispersions of midostaurin
WO2015001489A1 (en) Pharmaceutical compositions of ticagrelor
KR20100052453A (en) Method for the production of a medicament containing tadalafil
WO2017182455A1 (en) Stable pharmaceutical composition of amorphous ticagrelor
EP3110402A1 (en) Dapagliflozin compositions
WO2014170026A1 (en) Stabilized amorphous ticagrelor
WO2008027600A2 (en) Imatinib compositions
WO2015124995A1 (en) Solid dosage forms of rivaroxaban
WO2015110952A1 (en) Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
IL260085A (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
EP3556355B1 (en) Particles containing amorphous empagliflozin, process for their preparation and pharmaceutical preparation
WO2018229785A1 (en) Pharmaceutical compositions of ticagrelor
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
WO2010026597A1 (en) Oral dosage forms of linezolid and processes for their preparation
WO2011080706A1 (en) Enhanced solubility of ziprasidone
CA2934586A1 (en) Pharmaceutical composition
WO2021106004A1 (en) Pharmaceutical composition of s-adenosylmethionine
US11452722B2 (en) Stable pharmaceutical compositions comprising lenalidomide
EP2803353B1 (en) Compositions of Imatinib
US20150031737A1 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2010131265A1 (en) Novel pharmaceutical compositions of choline fenofibrate
TW201805003A (en) Pharmaceutical solid dispersion of a BCL-2 inhibitor, pharmaceutical compositions thereof, and uses for the treatment of cancer
EP3576735A1 (en) Pharmaceutical composition of everolimus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17913708

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17913708

Country of ref document: EP

Kind code of ref document: A1